A Phase 4 interventional study of TDF and Peg-IFN in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 171 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-26.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 2nd largest by enrollment, is one of 6 that started in 2011, is one of 22 in phase 4, and was the 17th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 6 started in 2011.
This study's enrollment of 751 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one has the largest enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 4, and was the 18th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) plus peginterferon α-2a (Peg-IFN) combination therapy for 48 weeks versus standard of care TDF monotherapy or Peg-IFN monotherapy for 48 weeks in non-cirrhotic adults with chronic hepatitis B virus (HBV) as determined by loss of hepatitis B surface antigen (HBsAg).
The study will consist of 2 phases for participants in the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups. Following an initial 48 weeks of treatment, participants in these groups will be monitored for 24 weeks for signs of worsening HBV, and those meeting TDF retreatment and flare management criteria will be eligible to receive TDF monotherapy during a retreatment phase, up to Week 120.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TDF plus Peg-IFN for 48 weeks
Drug: TDF · Drug: Peg-IFN
TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
Drug: TDF · Drug: Peg-IFN
TDF monotherapy for 120 weeks
Drug: TDF
Peg-IFN monotherapy for 48 weeks
Drug: Peg-IFN
Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.
Time frame: Baseline; Week 72
Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.
Time frame: Baseline; Week 72
Percentage of Participants With HBsAg Loss at Weeks 96 and 120
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.
Time frame: Baseline; Weeks 96 and 120
Percentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120
HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.
Time frame: Baseline; Weeks 72, 96, and 120
Percentage of Participants With HBeAg Loss and Seroconversion at Week 72
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.
Time frame: Baseline; Week 72
Percentage of Participants With HBeAg Loss and Seroconversion at Week 96
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.
Time frame: Baseline; Week 96
Percentage of Participants With HBeAg Loss and Seroconversion at Week 120
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.
Time frame: Baseline; Week 120
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 72
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.
Time frame: Week 72
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 96
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.
Time frame: Week 96
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 120
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.
Time frame: Week 120
Percentage of Participants With Normal ALT at Week 72
Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.
Time frame: Week 72
Percentage of Participants With Normal ALT at Week 96
Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.
Time frame: Week 96
Percentage of Participants With Normal ALT at Week 120
Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.
Time frame: Week 120
Percentage of Participants Who Required Retreatment
Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.
Time frame: Up to 120 weeks
Participants were enrolled at study sites in North America, Europe, Asia, and Australia. The first participant was screened on 12 April 2011. The last study visit occurred on 17 July 2015.
| Milestone | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Weeks | TDF 120 Weeks | Peg-IFN 48 Weeks |
|---|---|---|---|---|
| Started | 188 | 187 | 190 | 186 |
| Completed | 151 | 139 | 163 | 150 |
| Not completed | 37 | 48 | 27 | 36 |
| Withdrew: Adverse event | 5 | 3 | 0 | 7 |
| Withdrew: Withdrawal by subject | 18 | 21 | 8 | 17 |
| Withdrew: Lost to follow-up | 7 | 9 | 4 | 2 |
| Withdrew: Physician decision | 3 | 5 | 1 | 6 |
| Withdrew: Pregnancy | 2 | 2 | 4 | 1 |
| Withdrew: Noncompliance with study drug | 1 | 3 | 2 | 0 |
| Withdrew: Subject never dosed with study drug | 1 | 2 | 3 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 5 | 0 |
| Withdrew: Subject terminated from study by sponsor | 0 | 1 | 0 | 2 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.
| percentage of participants | TDF+Peg-IFN 48 Weeks | TDF 120 Weeks | Peg-IFN 48 Weeks |
|---|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone | 9.05 | 0.00 | 2.84 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.
| percentage of participants | TDF 48 Weeks + Peg-IFN 16 Weeks | TDF 120 Weeks | Peg-IFN 48 Weeks |
|---|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone | 2.83 | 0.00 | 2.84 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.
| percentage of participants | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Weeks | TDF 120 Week | Peg-IFN 48 Weeks |
|---|---|---|---|---|
| Week 96 | 9.69 | 3.49 | 0.00 | 2.84 |
| Week 120 | 10.36 | 3.49 | 0.00 | 3.51 |
HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.
| percentage of participants | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Weeks | TDF 120 Weeks | Peg-IFN 48 Weeks |
|---|---|---|---|---|
| Week 72 | 8.05 | 0.56 | 0.00 | 2.87 |
| Week 96 | 8.05 | 0.56 | 0.00 | 2.87 |
| Week 120 | 10.08 | 0.56 | 0.00 | 2.87 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.
| percentage of participants | TDF+Peg-IFN 48 Week (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| HBeAg Loss | 35.5 | 15.6 | 32.8 | 15.9 | 14.7 | 32.8 | 14.3 |
| HBeAg Seroconversion | 28.9 | 15.6 | 31.1 | 13.6 | 12.8 | 31.3 | 14.3 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.
| percentage of participants | TDF+Peg-IFN 48 Week (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| HBeAg Loss | 43.2 | 20.3 | 45.5 | 14.8 | 18.3 | 37.8 | 14.5 |
| HBeAg Seroconversion | 36.4 | 18.8 | 43.2 | 13.1 | 16.5 | 29.7 | 13.0 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.
| percentage of participants | TDF+Peg-IFN 48 Week (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| HBeAg Loss | 38.6 | 25.0 | 37.5 | 23.1 | 20.2 | 33.3 | 18.6 |
| HBeAg Seroconversion | 29.5 | 21.9 | 35.0 | 15.4 | 15.6 | 25.0 | 17.1 |
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.
| percentage of participants | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 72 | 15.3 | 26.2 | 14.5 | 15.1 | 84.9 | 11.7 | 40.4 |
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.
| percentage of participants | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 96 | 21.7 | 68.0 | 15.7 | 80.2 | 83.8 | 13.9 | 70.8 |
For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.
| percentage of participants | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 120 | 32.4 | 81.3 | 18.8 | 83.5 | 82.2 | 13.2 | 82.1 |
Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.
| percentage of participants | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Week (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| AASLD Criteria | 42.1 | 18.3 | 40.7 | 18.2 | 47.6 | 35.0 | 9.2 |
| Central Laboratory Criteria | 59.5 | 40.0 | 57.6 | 34.8 | 72.4 | 57.5 | 33.8 |
Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.
| percentage of participants | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Week (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| AASLD Criteria | 43.2 | 42.9 | 34.1 | 46.1 | 48.1 | 34.7 | 39.8 |
| Central Laboratory Criteria | 55.6 | 71.4 | 52.4 | 73.5 | 73.0 | 47.2 | 68.1 |
Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.
| percentage of participants | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Week (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| AASLD Criteria | 39.2 | 54.5 | 30.4 | 48.7 | 48.6 | 30.9 | 47.0 |
| Central Laboratory Criteria | 44.6 | 72.3 | 40.6 | 78.3 | 73.0 | 41.2 | 73.5 |
Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.
| percentage of participants | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Weeks | Peg-IFN 48 Weeks |
|---|---|---|---|
| Percentage of Participants Who Required Retreatment | 60.2 | 62.5 | 63.2 |
Collected over Up to 120 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TDF+Peg-IFN 48 Weeks (Not Retreated) | — | 21/186 (11.3%) | 147/186 (79%) |
| TDF+Peg-IFN 48 Weeks (Retreated) | — | 7/112 (6.3%) | 26/112 (23.2%) |
| TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated) | — | 18/184 (9.8%) | 142/184 (77.2%) |
| TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | — | 3/115 (2.6%) | 31/115 (27%) |
| TDF 120 Weeks | — | 13/185 (7%) | 89/185 (48.1%) |
| Peg-IFN 48 Weeks (Not Retreated) | — | 18/185 (9.7%) | 152/185 (82.2%) |
| Peg-IFN 48 Weeks (Retreated) | — | 6/117 (5.1%) | 33/117 (28.2%) |
| Event | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 6/186 | 3/112 | 8/184 | 2/115 | 1/185 | 7/185 | 2/117 |
| HepatitisHepatobiliary disorders | 3/186 | 2/112 | 4/184 | 0/115 | 1/185 | 7/185 | 1/117 |
| Aspartate aminotransferase increasedInvestigations | 1/186 | 2/112 | 1/184 | 0/115 | 0/185 | 2/185 | 1/117 |
| Cholecystitis chronicHepatobiliary disorders | 0/186 | 0/112 | 0/184 | 0/115 | 2/185 | 0/185 | 0/117 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/186 | 1/112 | 0/184 | 0/115 | 0/185 | 0/185 | 0/117 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/186 | 1/112 | 0/184 | 0/115 | 0/185 | 0/185 | 0/117 |
| Mixed hepatocellular cholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/186 | 1/112 | 0/184 | 0/115 | 0/185 | 0/185 | 0/117 |
| Hepatic encephalopathyNervous system disorders | 0/186 | 0/112 | 0/184 | 1/115 | 0/185 | 0/185 | 0/117 |
| Amylase increasedInvestigations | 0/186 | 0/112 | 0/184 | 0/115 | 0/185 | 0/185 | 1/117 |
| Lipase increasedInvestigations | 0/186 | 0/112 | 0/184 | 0/115 | 0/185 | 0/185 | 1/117 |
| Event | TDF+Peg-IFN 48 Weeks (Not Retreated) | TDF+Peg-IFN 48 Weeks (Retreated) | TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated) | TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated) | TDF 120 Weeks | Peg-IFN 48 Weeks (Not Retreated) | Peg-IFN 48 Weeks (Retreated) |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 54/186 | 3/112 | 37/184 | 3/115 | 16/185 | 52/185 | 4/117 |
| AlopeciaSkin and subcutaneous tissue disorders | 46/186 | 0/112 | 32/184 | 1/115 | 2/185 | 45/185 | 1/117 |
| PyrexiaGeneral disorders | 39/186 | 1/112 | 36/184 | 1/115 | 8/185 | 43/185 | 2/117 |
| FatigueGeneral disorders | 40/186 | 2/112 | 33/184 | 4/115 | 21/185 | 41/185 | 6/117 |
| Decreased appetiteMetabolism and nutrition disorders | 23/186 | 0/112 | 36/184 | 2/115 | 2/185 | 18/185 | 0/117 |
| MyalgiaMusculoskeletal and connective tissue disorders | 29/186 | 0/112 | 36/184 | 1/115 | 2/185 | 35/185 | 1/117 |
| NauseaGastrointestinal disorders | 26/186 | 0/112 | 24/184 | 3/115 | 11/185 | 13/185 | 6/117 |
| PruritusSkin and subcutaneous tissue disorders | 14/186 | 0/112 | 14/184 | 2/115 | 4/185 | 21/185 | 0/117 |
| NasopharyngitisInfections and infestations | 5/186 | 3/112 | 16/184 | 3/115 | 20/185 | 6/185 | 3/117 |
| AstheniaGeneral disorders | 20/186 | 0/112 | 9/184 | 1/115 | 4/185 | 12/185 | 1/117 |
Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants were analyzed by actual treatment received. 11 participants were never dosed are not included in the Safety Analysis Set due to the following reasons for discontinuation: 7 = Subject Never Dosed with Study Drug; 4 = Withdrawal by Subject.
| Age, Continuous(years) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Mean | 38 ± 10.7 | 37 ± 9.9 | 36 ± 10.8 | 38 ± 10.5 | 37 ± 10.5 |
| Sex: Female, Male(Participants) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Female | 59 | 65 | 64 | 66 | 254 |
| Male | 127 | 119 | 121 | 119 | 486 |
| Ethnicity (NIH/OMB)(Participants) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 3 | 7 | 18 |
| Not Hispanic or Latino | 182 | 179 | 181 | 177 | 719 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 3 |
| Race/Ethnicity, Customized(participants) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Asian | 142 | 134 | 141 | 137 | 554 |
| Black or African American | 5 | 3 | 4 | 6 | 18 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 1 | 3 |
| White | 36 | 45 | 39 | 41 | 161 |
| Other | 1 | 2 | 1 | 0 | 4 |
| Region of Enrollment(participants) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Romania | 12 | 15 | 13 | 9 | 49 |
| Singapore | 7 | 5 | 7 | 8 | 27 |
| Hong Kong | 25 | 24 | 27 | 21 | 97 |
| United States | 19 | 17 | 23 | 26 | 85 |
| United Kingdom | 2 | 3 | 1 | 4 | 10 |
| Portugal | 0 | 3 | 0 | 0 | 3 |
| India | 10 | 5 | 9 | 6 | 30 |
| Spain | 3 | 3 | 3 | 5 | 14 |
| Greece | 0 | 3 | 2 | 4 | 9 |
| Canada | 19 | 14 | 14 | 11 | 58 |
| Netherlands | 2 | 1 | 0 | 1 | 4 |
| Turkey | 5 | 6 | 6 | 7 | 24 |
| Taiwan | 20 | 15 | 12 | 19 | 66 |
| Korea, Republic of | 34 | 38 | 38 | 35 | 145 |
| Poland | 4 | 7 | 6 | 5 | 22 |
| Italy | 2 | 1 | 4 | 4 | 11 |
| Australia | 10 | 14 | 15 | 14 | 53 |
| France | 6 | 3 | 1 | 3 | 13 |
| Germany | 6 | 7 | 4 | 3 | 20 |
| Hepatitis B Surface Antigen (HBsAg)(log 10 IU/mL) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Mean | 3.88 ± 0.840 | 3.84 ± 0.849 | 3.89 ± 0.812 | 3.76 ± 0.844 | 3.84 ± 0.836 |
| Hepatitis B e Antigen (HBeAg) Status(participants) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Reactive | 108 | 105 | 109 | 106 | 428 |
| Nonreactive | 78 | 79 | 76 | 79 | 312 |
| Hepatitis B Virus (HBV) DNA(log 10 IU/mL) | TDF+Peg-IFN 48 Weeks | TDF 48 Weeks + Peg-IFN 16 Week | TDF 120 Weeks | Peg-IFN 48 Weeks | Total |
|---|---|---|---|---|---|
| Mean | 7.06 ± 1.542 | 7.13 ± 1.505 | 7.02 ± 1.550 | 6.94 ± 1.619 | 7.04 ± 1.553 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2011, a primary completion of Aug 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tenofovir · Interferons